Literature DB >> 20381072

Effect of selective serotonin re-uptake inhibitors (SSRIs) on functional outcome in patients with acute ischemic stroke treated with tPA.

I Miedema1, K M Horvath, M Uyttenboogaart, K Koopman, M M H Lahr, J De Keyser, G J Luijckx.   

Abstract

BACKGROUND: Selective serotonin re-uptake inhibitors (SSRIs) may have therapeutic potential in the treatment of ischemic stroke by effects on neuronal cell survival and the plasticity of brain processes. In the present study, we investigated whether prior treatment with a SSRI is associated with more favorable functional outcome in a cohort of patients with acute ischemic stroke treated with tissue plasminogen activator (tPA).
METHODS: In a prospective observational cohort study of 476 acute ischemic stroke patients treated with tPA we investigated the relationship between prior SSRI treatment and functional outcome at 3 months. Ischemic stroke subtypes were defined according to the Oxfordshire Community Stroke Project Classification. Favorable outcome was defined as a modified Rankin Scale score <or=2.
RESULTS: In the cohort of 476 patients, 22 (5%) patients used a SSRI at stroke onset. At 3 months, 217 (46%) patients had a favorable outcome of whom 9 (41%) on SSRI treatment and 208 (46%) not using SSRIs (p=0.65). In a multivariable analysis SSRI treatment showed a trend to association with unfavorable outcome (OR 0.4, 95% CI 0.14-1.13, p=0.08). In the 376 patients with cortical stroke, SSRI treatment was associated with an unfavorable outcome (OR 0.17, 95% CI 0.04-0.73, p=0.017).
CONCLUSION: Our data suggest that in patients with acute ischemic stroke treated with tPA, prior SSRI use may be associated with a less favorable outcome, especially in cortical stroke. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381072     DOI: 10.1016/j.jns.2010.03.004

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

Review 1.  Executive (dys)function after stroke: special considerations for behavioral pharmacology.

Authors:  Jessica M Povroznik; Jenny E Ozga; Cole Vonder Haar; Elizabeth B Engler-Chiurazzi
Journal:  Behav Pharmacol       Date:  2018-10       Impact factor: 2.293

Review 2.  Potential Role of Selective Serotonin Reuptake Inhibitors in Improving Functional Outcome after Stroke.

Authors:  Janne Kaergaard Mortensen; Grethe Andersen
Journal:  CNS Drugs       Date:  2018-10       Impact factor: 5.749

Review 3.  Selective serotonin reuptake inhibitors for functional recovery after stroke: similarities with the critical period and the role of experience-dependent plasticity.

Authors:  Colleen L Schneider; Ania K Majewska; Ania Busza; Zoe R Williams; Bradford Z Mahon; Bogachan Sahin
Journal:  J Neurol       Date:  2019-07-25       Impact factor: 4.849

4.  Exploring new frontiers in neuropsychopharmacology: SSRIs for stroke.

Authors:  T S Sathyanarayana Rao; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2011-10       Impact factor: 1.759

5.  Biosensors for brain trauma and dual laser doppler flowmetry: enoxaparin simultaneously reduces stroke-induced dopamine and blood flow while enhancing serotonin and blood flow in motor neurons of brain, in vivo.

Authors:  Patricia A Broderick; Edwin H Kolodny
Journal:  Sensors (Basel)       Date:  2010-12-24       Impact factor: 3.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.